06.25.21
WEHI collaborates with Boehringer Ingelheim to develop novel anti-cancer therapeutics
WEHI has partnered with Boehringer Ingelheim, a leading research-driven pharmaceutical company, in a collaboration to discover and develop anti-cancer therapeutics using a promising new technology called targeted protein degradation. The partnership builds on more than 25 years of pioneering discoveries at WEHI, into a family of proteins known as the inhibitor of apoptosis proteins (IAPs)